Nature Biotechnology
- 24, 871 - 872 (2006)
Published online: 3 August 2006; | doi:10.1038/nbt0806-871
Bundling next-generation cancer therapies for synergyJim Kling
Bellingham, Washington
Biotech companies are now in a race to go beyond the limitations of existing targeted therapies either by finding complementary treatments or by combining already approved therapies to synergize their effect
|
